NCT01338792View on ClinicalTrials.gov

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions
Hormone-resistant Prostate CancerRecurrent Prostate Cancer
Interventions
DRUG

oxaliplatin

Given IV

DRUG

pemetrexed disodium

Given IV

OTHER

questionnaire administration

Ancillary studies

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

reverse transcriptase-polymerase chain reaction

Correlative studies

GENETIC

polymorphism analysis

Correlative studies

Trial Locations (1)

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT01338792 - Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter